Go Back This article was viewed 51 times

Original Article


The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor

Kalpesh Mahesh ParmarMamta SinglaArup Kumar MandalShalmoli BhattacharyaSharwan Kumar Singh
Departments of Urology1Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 
Corresponding Author:

Kalpesh Mahesh Parmar

Departments of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
E-mail: kalpesh010385@gmail.com

Corresponding Author:

Kalpesh Mahesh Parmar

Departments of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
E-mail: kalpesh010385@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20172646

ABSTRACT


Background: Latest advances indicate that RUNX3 is a candidate tumor suppressor in several types of human cancers, including renal cell cancer. However, its definitive role is not yet established. Vascular endothelial growth factor (VEGF) has been widely studied as a surrogate marker of angiogenic activity and prognostic marker in renal cancer for monitoring treatment response and detection of early relapse. The aim of the study was to examine the clinical significance of RUNX3 expression and serum VEFG in series of renal cancer patients using quantitative real-time polymerase chain reaction and standard enzyme-linked immunosorbent assay kit and find its correlation with renal cancer stage, grade, and histopathology. Materials and Methods: We reviewed our prospectively collected renal cancer database of 47 patients. All patients were evaluated preoperatively and staged and underwent partial or radical nephrectomy as per the feasibility criteria. RUNX 3 expression in tumor tissue and adjoining parenchyma was sampled in all patients, and serum levels of VEGF were measured in pre-and post-operative period on day 7 and day 30 after surgery. 10 age- and sex-matched healthy volunteers served as control group. Results: We observed that RUNX3 gene expression was significantly lower in tumor tissue than in normal renal parenchyma of a renal cancer patient. The serum VEGF levels were significantly increased in patients with renal cell carcinoma (RCC) compared to normal healthy volunteers and showed decreasing trend after the surgery. Loss of RUNX3 gene expression and higher VEGF levels strongly correlated with high-grade tumors; however, it was not related to tumor size and histopathology. There was no correlation of RUNX 3 with VEGF levels in RCC patients. Conclusion: The results of this study showed that renal cancer patients had increased VEGF levels which were effectively alleviated by curative resection. Lower expression of RUNX3 in renal cancer suggests its tumor suppressive role and new insights into targeted therapies linking RUNX3 gene may have some diagnostic and therapeutic implications in RCC patients. We did not find any correlation between RUNX3 gene and serum VEGF.
Keywords: Renal cell cancer, RUNX3, Vascular endothelial growth factor

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.